Category Archives: Global News Feed

OAKLAND, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Purple City Labs, a plant molecular biology company developing germplasm and technologies for the management of breeding programs and nurseries, is rolling out a Reverse Transcription- Loop Mediated Isothermal Amplification (RT-LAMP) based assay for testing and surveillance of Hop Latent Viroid.

Read the original:
Purple City Labs Introduces OnSight, a Molecular Assay for In-house Testing of Hop Latent Viroid

SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the 41st Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, CA January 9-12, 2023.

Continued here:
BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

The rest is here:
Tulsa ER & Hospital Adopts Trailblazing MeMed BV® Test

ISELIN, N.J., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the validation of its Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). The formal review process of the MAA by the EMA’s Committee for Medicinal Products for Human Use (CHMP) is now set to begin with an estimated decision date expected in early 2024.

See the rest here:
Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for...

- Features Alzheimer’s Experts: Christopher van Dyck, M.D. and Anton Porsteinsson, M.D. -

Excerpt from:
Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease

KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced the completion of its public offering of 4,764,674 Series J common shares (“Public Offering”).

Read this article:
Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million

- Ceapro is pioneering approach with a natural product as a potential anti-inflammatory

Link:
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets

PRESS RELEASE

See the article here:
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank

TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced that it has submitted the Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.

Read the original:
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in...

Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced changes in the Executive Committee effective 1 January 2023.

Go here to read the rest:
Galapagos announces changes to Executive Committee